KR900701840A - 인슐린 유사체 - Google Patents

인슐린 유사체

Info

Publication number
KR900701840A
KR900701840A KR1019900700042A KR900700042A KR900701840A KR 900701840 A KR900701840 A KR 900701840A KR 1019900700042 A KR1019900700042 A KR 1019900700042A KR 900700042 A KR900700042 A KR 900700042A KR 900701840 A KR900701840 A KR 900701840A
Authority
KR
South Korea
Prior art keywords
positions
amino acid
asn
gln
insulin
Prior art date
Application number
KR1019900700042A
Other languages
English (en)
Inventor
요르겐 베일가르트 브랑게 엔스
하벨운트 스벤트
Original Assignee
안네 제헤르
노브-노르디스크 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안네 제헤르, 노브-노르디스크 아크티에 셀스카브 filed Critical 안네 제헤르
Publication of KR900701840A publication Critical patent/KR900701840A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

인슐린 유사체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. Asn이 A18,A21 및 B3의 1 또는그 이상의 위치에 존재하지 않거나 및/ 또는 Gln이 A5,A15 및 B4의 1 또는 그 이상의 위치에 존재하지 않으며, 다한 A21위치의 아미노산 잔기가 Asn과 다를 때, A15,B4 또는 A5위치의 아미노산 잔기의 하나가 Gln과 다르거나 또는 A18 또는 B3위치의 아미노산 잔기의 하나가 Asn과 다르고, 그리고 다만 A5위치의 아미노산 잔기가 Gln과 다를 때 A15 또는 B4위치의 아미노산 잔기의 하나가 Gln과 다르거나 또는 A18,A21 또는 B3위치의 아미노산 잔기의 하나가 Asn과 다른 것을 특징으로 하는 인슐린 유사체.
  2. 제1항에 있어서, Asn이 A18,A21 및 B3의 1 또는 그 이상의 위치에 존재하지 않거나 및/ 또는 Gln이 A15및/ 또는 B4위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  3. 제1항에 있어서, Asn이 A18,A21 및 B3의 1 또는 그 이상의 위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  4. 제1항에 있어서, Asn이 B3및 A18위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  5. 제1항에 있어서, Asn이 B3및 A21위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  6. 제1항에 있어서, Asn이 B3위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  7. 제1항에 있어서, Asn이 B3및 A21위치에 존재하지 않고 Gln이 A15위치에 존재하지 않는 것을 특징으로 하는 인슐린 유사체.
  8. 제1항에 있어서, A18,A21 또는 B3위치에서 1 또는 그 이상의 아미노산 잔기가Glu,Asp,His,Ser,Thr,Val,Leu,lle,Ala,Met,Trp,Tyr,Gly 또는 Gln이고 및/ 또는 A5,A15및 B4위치에서 1 또는 그 이상의 아미노산 잔기가 Glu,Asp.His,Ser,Thr,Val,Leu,Ile,Ala,Met,Trp,Tyr 또는 Gly인 것을 특징으로 하는 인슐린 유사체.
  9. 제1항에 있어서, B3위치의 아미노산 잔기가 Asp,Gln,Ser,Thr 또는 Glu인 것을 특징으로 하는 인슐린 유사체.
  10. 상기 항의 어느 한 항에 따른 인슐린 유사체 또는 그것의 약학적으로 허용되는 염을 함유하는 것을 특징으로 하는 인슐린 환성을 가지는 인슐린 제제.
  11. LysB29가 GlyA1에 펩티드 결합 또는 다음식(I)
    -Ra-R1- (I)
    의 펩티드 사슬에 의하여 연결된 인슐린 우사제의 전구제를 코드하는 DNA-서열을 구성된 복제가능한 발현 비히클로 형질전환된 이스트 균주를 적당한 배지에서 배양하고, 배양액으로 부터 전구체를 회수하여 다음식 (Ⅱ)
    Q-0R″ (Ⅱ)
    의 아미노 화합물과 반응시키고, 물 및 유기용매의 혼합물중에서 촉매로서 트립신 또는 트립신-유사효소를 사용하고 가수분해에 의해 카르복시 보호기를 제거하는 것을 특징으로 하는 제1항에 따른 인간 인슐린의 제조 방법.
    다만 상기 식 (I)에서 R은 n개의 아미노산 잔기를 가지는 펩티드 사슬이고 n은 O내지 33의 정수이고 R1은 Lys 또는 Arg이며, 상기 식 (Ⅱ)에서 Q는 B3O위치에 삽입되는 바람직하게는 Thr인 아미노산 잔기이고 R은 카르복시 보호기이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700042A 1988-05-11 1989-05-10 인슐린 유사체 KR900701840A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK88,2579 1988-05-11
DK257988A DK257988D0 (da) 1988-05-11 1988-05-11 Nye peptider
PCT/DK1989/000117 WO1989010937A1 (en) 1988-05-11 1989-05-10 Insulin analogues

Publications (1)

Publication Number Publication Date
KR900701840A true KR900701840A (ko) 1990-12-04

Family

ID=8113334

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700042A KR900701840A (ko) 1988-05-11 1989-05-10 인슐린 유사체

Country Status (10)

Country Link
EP (1) EP0419504B1 (ko)
KR (1) KR900701840A (ko)
AU (1) AU615760B2 (ko)
DE (1) DE68912777T2 (ko)
DK (1) DK257988D0 (ko)
HU (1) HUT55442A (ko)
IE (1) IE65504B1 (ko)
NZ (1) NZ229108A (ko)
WO (1) WO1989010937A1 (ko)
ZA (1) ZA893508B (ko)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU641631B2 (en) * 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
US5716927A (en) * 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
DK155690D0 (da) * 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DK1265630T3 (da) 2000-03-24 2006-10-09 Genentech Inc Anvendelse af insulin til behandling af brusksygdomme
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
CA2621344C (en) 2005-09-14 2014-12-16 Sanofi-Aventis Deutschland Gmbh Cleavage of precursors of insulins by a variant of trypsin
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
NZ586590A (en) * 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
SI2451437T1 (sl) 2009-07-06 2017-03-31 Sanofi-Aventis Deutschlad Gmbh Vodni pripravki, ki vsebujejo metionin
US20120232002A1 (en) * 2009-07-06 2012-09-13 Sanofi-Aventis Deutschland Gmbh Slow-acting insulin preparations
EP2451472A1 (de) 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Hitze- und schüttelstabile insulinzubereitungen
EP2459228B1 (en) 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an insulin linker conjugate
JP5732053B2 (ja) 2009-07-31 2015-06-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 持続型インスリン組成物
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
RU2014127270A (ru) 2011-12-15 2016-02-10 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Аналог человеческого инсулина и его ацилированное производное
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
DK2854841T3 (en) 2012-06-04 2017-05-22 Diamedica Inc Kallikrein-1-glycosylation isoforms of human tissue
NZ707160A (en) 2012-12-19 2016-08-26 Wockhardt Ltd A stable aqueous composition comprising human insulin or an analogue or derivative thereof
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2015044922A1 (en) 2013-09-30 2015-04-02 Wockhardt Limited Pharmaceutical composition
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
AU2015205621A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3260548A1 (en) 2016-06-21 2017-12-27 Enzypep B.V. Enzymatic coupling of (oligo)peptides to the b-chain of an insulin receptor ligand
WO2018109162A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2536040A1 (de) * 1975-08-13 1977-02-24 Hoechst Ag Insulin-analoga mit biologischer wirkung
NZ187300A (en) * 1977-05-27 1982-08-17 Univ California Dna transfer vector and micro-organism modified to contain a nucleotide sequence equivalent to the gene of a higher organism
US4343898A (en) * 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
IE62879B1 (en) * 1987-02-25 1995-03-08 Novo Nordisk As Novel insulin derivatives

Also Published As

Publication number Publication date
IE65504B1 (en) 1995-11-01
DE68912777T2 (de) 1994-05-11
HU893263D0 (en) 1991-03-28
DE68912777D1 (de) 1994-03-10
IE891536L (en) 1989-11-11
AU3692889A (en) 1989-11-29
ZA893508B (en) 1990-01-31
EP0419504A1 (en) 1991-04-03
DK257988D0 (da) 1988-05-11
NZ229108A (en) 1992-05-26
EP0419504B1 (en) 1994-01-26
WO1989010937A1 (en) 1989-11-16
HUT55442A (en) 1991-05-28
AU615760B2 (en) 1991-10-10

Similar Documents

Publication Publication Date Title
KR900701840A (ko) 인슐린 유사체
KR910700262A (ko) 사람 인슐린 유사체
KR870002165A (ko) 인슈린유사체 및 그의 제조방법
KR930009591A (ko) 트리-아르기닌 인슐린
KR850008681A (ko) 합성펩티드의 제조방법
EP0525838A3 (en) Growth hormone releasing factor analogs
AU566180B2 (en) Human pancreatic grf
KR930701483A (ko) Grf (쥐이알에프) 유사체 xi
US4098778A (en) β-Endorphin analog
CA1187872A (en) Pharmacologically active peptides
CA2002924A1 (en) Anti-Thrombins
RU2001101164A (ru) Новые аналоги инсулина с повышенным связыванием цинка
Lemaire et al. Synthesis and biological activity of. beta.-endorphin and analogs. Additional evidence for multiple opiate receptors
US4283329A (en) Pharmacologically active peptides
EP0018182B1 (en) Peptides having thymopoietin-like activity, therapeutic compositions containing them, and process for their preparation
US4397842A (en) Peptides having thymopoietin-like activity
Schwartz et al. Synthesis of des (tetrapeptide B1-4) and des (pentapeptide B1-5) human insulin. Two biologically active analogs
EP0292257A3 (en) Peptides having anf activity
Yamamoto et al. Synthesis of porcine leumorphin and some of its biological activities
KR850700246A (ko) Crf 유사체
EP0008196B1 (en) Pentapeptides, processes for their preparation, intermediates used in such processes, use in pharmaceutical compositions and compositions containing them
KR900701839A (ko) Crf 유사체
US4128541A (en) Pentapeptide with morphine- like activity
LILI et al. Studies on peptides. CLXV. Combination of a new amide-precursor reagent and trimethylsilyl bromide deprotection for the 9-fluorenylmethyloxycarbonyl-based solid-phase synthesis of chicken antral peptide
US4317770A (en) D-amino acid analogs of beta-endorphin

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E601 Decision to refuse application